Moderna, Inc. (NASDAQ:MRNA - Get Free Report) President Stephen Hoge sold 15,000 shares of Moderna stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $105.02, for a total value of $1,575,300.00. Following the completion of the sale, the president now owns 1,486,241 shares of the company's stock, valued at $156,085,029.82. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Stephen Hoge also recently made the following trade(s):
- On Thursday, February 29th, Stephen Hoge sold 2,388 shares of Moderna stock. The shares were sold at an average price of $94.57, for a total value of $225,833.16.
Moderna Price Performance
Shares of MRNA stock opened at $103.44 on Thursday. The stock's 50-day simple moving average is $100.10 and its 200-day simple moving average is $93.52. The firm has a market capitalization of $39.61 billion, a price-to-earnings ratio of -8.34 and a beta of 1.62. Moderna, Inc. has a fifty-two week low of $62.55 and a fifty-two week high of $144.93. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.36 and a current ratio of 3.42.
The biggest energy story ever?
From Porter & Company | Ad
Discover why I’m calling this one of the biggest developments in the global energy market since the shale revolution… why everything you’ve ever been told about Trump’s environmental record is a lie…
For the full story, click here.
Moderna (NASDAQ:MRNA - Get Free Report) last issued its earnings results on Thursday, February 22nd. The company reported $0.55 EPS for the quarter, beating analysts' consensus estimates of ($0.78) by $1.33. The firm had revenue of $2.80 billion for the quarter, compared to analyst estimates of $2.53 billion. Moderna had a negative return on equity of 10.23% and a negative net margin of 68.84%. Moderna's revenue for the quarter was down 44.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $3.61 earnings per share. As a group, equities analysts forecast that Moderna, Inc. will post -7.51 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Moderna
A number of large investors have recently bought and sold shares of MRNA. Cim Investment Management Inc. lifted its holdings in Moderna by 4.2% in the first quarter. Cim Investment Management Inc. now owns 2,139 shares of the company's stock valued at $329,000 after acquiring an additional 86 shares during the period. Cetera Advisor Networks LLC lifted its holdings in Moderna by 0.5% in the fourth quarter. Cetera Advisor Networks LLC now owns 17,195 shares of the company's stock valued at $3,088,000 after acquiring an additional 87 shares during the period. Ancora Advisors LLC lifted its holdings in Moderna by 41.2% in the first quarter. Ancora Advisors LLC now owns 329 shares of the company's stock valued at $51,000 after acquiring an additional 96 shares during the period. Sunbelt Securities Inc. lifted its holdings in Moderna by 7.5% in the first quarter. Sunbelt Securities Inc. now owns 1,428 shares of the company's stock valued at $211,000 after acquiring an additional 100 shares during the period. Finally, Allworth Financial LP lifted its holdings in Moderna by 6.5% in the fourth quarter. Allworth Financial LP now owns 1,660 shares of the company's stock valued at $165,000 after acquiring an additional 101 shares during the period. Hedge funds and other institutional investors own 75.33% of the company's stock.
Wall Street Analysts Forecast Growth
Several analysts recently weighed in on the company. Royal Bank of Canada restated an "outperform" rating and issued a $125.00 price objective on shares of Moderna in a report on Thursday, March 28th. Oppenheimer upgraded Moderna from a "market perform" rating to an "outperform" rating and set a $142.00 target price on the stock in a research note on Tuesday, January 2nd. HSBC reiterated a "reduce" rating and issued a $86.00 target price (up previously from $75.00) on shares of Moderna in a research note on Monday, February 26th. Canaccord Genuity Group lifted their target price on Moderna from $82.00 to $91.00 and gave the company a "hold" rating in a research note on Friday, February 23rd. Finally, Jefferies Financial Group reiterated a "buy" rating and issued a $125.00 target price on shares of Moderna in a research note on Tuesday, April 9th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and six have assigned a buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $126.49.
View Our Latest Analysis on MRNA
Moderna Company Profile
(
Get Free Report)
Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
